Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort

Published:2019-04-12 Issue:10 Volume:49 Page:1323-1333
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Scheiner Bernhard¹^ORCID,Kirstein Martha M.²,Hucke Florian³,Finkelmeier Fabian⁴^ORCID,Schulze Kornelius⁵,von Felden Johann⁵^ORCID,Koch Sandra⁶,Schwabl Philipp¹,Hinrichs Jan B.²,Waneck Fredrik¹,Waidmann Oliver⁴,Reiberger Thomas¹^ORCID,Müller Christian¹,Sieghart Wolfgang¹,Trauner Michael¹,Weinmann Arndt⁶,Wege Henning⁵,Trojan Jörg⁴,Peck-Radosavljevic Markus³,Vogel Arndt²,Pinter Matthias¹^ORCID

Affiliation:

1. Vienna Austria

2. Hannover Germany

3. Klagenfurt Austria

4. Frankfurt/Main Germany

5. Hamburg Germany

6. Mainz Germany

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.15245/fullpdf

Reference38 articles.

1. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma;Galle;J Hepatol,2018

2. Clinical characteristics of patients with hepatocellular carcinoma in Austria - is there a need for a structured screening program?;Hucke;Wien Klin Wochenschr,2011

3. Epidemiological trends of hepatocellular carcinoma in Austria;Pinter;Dig Dis,2014

4. Cancer and liver cirrhosis: implications on prognosis and management;Pinter;ESMO Open,2016

5. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Vogel;Ann Oncol,2018

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolution of liver function during immune checkpoint inhibitor treatment for hepatocellular carcinoma;United European Gastroenterology Journal;2024-07-11

2. The impact of PD-1 inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a retrospective study;Scientific Reports;2024-06-21

3. Nivolumab as Second-Line Therapy Improves Survival in Patients with Unresectable Hepatocellular Carcinoma;Cancers;2024-06-11

4. Regulatory T cells as crucial trigger and potential target for hyperprogressive disease subsequent to PD-1/PD-L1 blockade for cancer treatment;International Immunopharmacology;2024-05

5. Comparative efficacy and safety of cabozantinib for malignant tumors: a systematic review and meta-analysis;Expert Review of Anticancer Therapy;2024-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3